2017
DOI: 10.1038/s41409-017-0032-1
|View full text |Cite
|
Sign up to set email alerts
|

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 18 publications
1
1
0
Order By: Relevance
“…The median follow-up was 44 months and 3-year PFS, OS, incidence of relapse, and NRM after the tandem were 53%, 73%, 34%, and 13%, respectively. A similar result was reported by Mariotti et al in another study (115). The results suggest that this might be an effective treatment for a high-risk population.…”
Section: Tandem Autologous-allogeneic Transplantationsupporting
confidence: 90%
“…The median follow-up was 44 months and 3-year PFS, OS, incidence of relapse, and NRM after the tandem were 53%, 73%, 34%, and 13%, respectively. A similar result was reported by Mariotti et al in another study (115). The results suggest that this might be an effective treatment for a high-risk population.…”
Section: Tandem Autologous-allogeneic Transplantationsupporting
confidence: 90%
“…HDT/ASCT has been traditionally reserved for patients with chemosensitive relapse due to a more favorable outcome for those achieving a complete metabolic response at the time of PET scan [26]. In the pre-novel agent's era, only a small fraction of patients refractory to first-line ST were rescued by strategies employing tandem autologous [27] or tandem autologous-allogeneic transplantation [28,29]. Since the introduction of novel agents as a second-or third-salvage line of therapy, the best consolidation strategy has been a matter of debate.…”
Section: Discussionmentioning
confidence: 99%